Regeneron Bounces Back With Approval of Two Drugs From Catalent Plant

August 21, 2023 |

After suffering the setback of a complete response letter (CRL) concerning its contract manufacturing plant, Regeneron has bounced back with FDA approval of two drugs — Eylea HD (aflibercept 8 mg) and Veopoz (pozelimab-bbfg).
Source: Drug Industry Daily